FDA label 8860d098-4ab6-4445-b629-57f1a4075e23
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- b4627e0f-4a69-41d4-b4f1-3b54bbdc5c4f
- SPL ID
- 8860d098-4ab6-4445-b629-57f1a4075e23
- Version
- 2
- Effective date
- 2025-04-04
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:33:32
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 8860d098-4ab6-4445-b629-57f1a4075e23 | id | |
| spl set id | b4627e0f-4a69-41d4-b4f1-3b54bbdc5c4f | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Seizure occurred in 0.5% of patients receiving enzalutamide. In patients with predisposing factors, seizures were reported in 2.2% of patients. Permanently discontinue enzalutamide in patients who develop a seizure during treatment. ( 5.1 ) Posterior reversible encephalopathy syndrome (PRES): Discontinue enzalutamide. ( 5.2 ) Hypersensitivity: Discontinue enzalutamide. ( 5.3 ) Ischemic Heart Disease: Optimize management of cardiovascular risk factors. Discontinue enzalutamide for Grade 3 to 4 adverse reactions. ( 5.4 ) Falls and Fractures: Evaluate patients for fracture and fall risk, and treat patients with bone-targeted agents according to established guidelines. ( 5.5 ) Embryo-Fetal Toxicity: Enzalutamide can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception. ( 5.6 , 8.1 , 8.3 ) Severe Dysphagia or Choking Related to Product Size: Discontinue enzalutamide for patients who cannot swallow capsules. ( 2.1 , 5.7 ) 5.1 Seizure Seizure occurred in 0.5% of patients receiving enzalutamide in seven randomized clinical trials. In these trials, patients with predisposing factors for seizure were generally excluded. Seizure occurred from 13 to 1,776 days after initiation of enzalutamide. Patients experiencing seizure were permanently discontinued from therapy, and all seizure events resolved. In a single-arm trial designed to assess the risk of seizure in patients with pre-disposing factors for seizure, 8 of 366 (2.2%) enzalutamide-treated patients experienced a seizure. Three of the 8 patients experienced a second seizure during continued treatment with enzalutamide after their first seizure resolved. It is unknown whether anti-epileptic medications will prevent seizures with enzalutamide. Patients in the study had one or more of the following pre-disposing factors: the use of medications that may lower the seizure threshold (~ 54%), history of traumatic brain or head injury (~ 28%), history of cerebrovascular accident or transient ischemic attack (~ 24%), and Alzheimer's disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, past history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection (all < 5%). Approximately 17% of patients had more than one risk factor. Advise patients of the risk of developing a seizure while receiving enzalutamide and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Permanently discontinue enzalutamide in patients who develop a seizure during treatment. 5.2 Posterior Reversible Encephalopathy Syndrome (PRES) There have been reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving enzalutamide [see Adverse Reactions ( 6.2 )] . PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue enzalutamide in patients who develop PRES. 5.3 Hypersensitivity Hypersensitivity reactions, including edema of the face (0.5%), tongue (0.1%), or lip (0.1%) have been observed with enzalutamide in seven randomized clinical trials. Pharyngeal edema has been reported in post-marketing cases. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue enzalutamide and promptly seek medical care. Permanently discontinue enzalutamide for serious hypersensitivity reactions. 5.4 Ischemic Heart Disease In the combined data of four randomized, placebo-controlled clinical studies, ischemic heart disease occurred more commonly in patients on the enzalutamide arm compared to patients on the placebo arm (2.9% vs 1.3%). Grade 3-4 ischemic events occurred in 1.4% of patients on the enzalutamide arm compared to 0.7% on the placebo arm. Ischemic events led to death in 0.4% of patients on the enzalutamide arm compared to 0.1% on the placebo arm. Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue enzalutamide for Grade 3-4 ischemic heart disease. 5.5 Falls and Fractures Falls and fractures occurred in patients receiving enzalutamide. Evaluate patients for fracture and fall risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents. In the combined data of four randomized, placebo-controlled clinical studies, falls occurred in 11% of patients treated with enzalutamide compared to 4% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Fractures occurred in 10% of patients treated with enzalutamide and in 4% of patients treated with placebo. Grade 3 to 4 fractures occurred in 3% of patients treated with enzalutamide and in 2% of patients treated with placebo. The median time to onset of fracture was 336 days (range: 2 to 1,914 days) for patients treated with enzalutamide. Routine bone density assessment and treatment of osteoporosis with bone-targeted agents were not performed in the studies. 5.6 Embryo-Fetal Toxicity The safety and efficacy of enzalutamide have not been established in females. Based on animal reproductive studies and mechanism of action, enzalutamide can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment with enzalutamide and for 3 months after the last dose of enzalutamide [see Use in Specific Populations ( 8.1 , 8.3 )] . 5.7 Dysphagia or Choking Severe dysphagia or choking, including events that could be life-threatening requiring medical intervention or fatal, can occur due to enzalutamide product size. Advise patients to take each capsule o with a sufficient amount of water to ensure that all medication is successfully swallowed. Discontinue enzalutamide for patients who cannot swallow capsules.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following is discussed in more detail in other sections of the labeling: Seizure [see Warnings and Precautions ( 5.1 )] Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions ( 5.2 )] Hypersensitivity [see Warnings and Precautions ( 5.3 )] Ischemic Heart Disease [see Warnings and Precautions ( 5.4 )] Falls and Fractures [see Warnings and Precautions ( 5.5 )] Dysphagia or Choking [see Warnings and Precautions ( 5.7 )] The most common adverse reactions (≥ 10%) that occurred more frequently (≥ 2% over placebo) in the enzalutamide-treated patients are musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhea, hypertension, hemorrhage, fall, fracture, and headache. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in WARNINGS and PRECAUTIONS reflect seven randomized, controlled trials [AFFIRM, PREVAIL, TERRAIN, PROSPER, ARCHES, Asian PREVAIL (NCT02294461), and STRIVE (NCT01664923)] that were pooled to conduct safety analyses in patients with CRPC (N= 3,651 mCSPC (N= 752)) treated with enzalutamide. Patients received enzalutamide 160 mg (N= 4,081) or placebo orally once daily (N= 2,472) or bicalutamide 50 mg orally once daily (N= 387). In these seven trials, the median duration of treatment was 13.8 months (range: <0.1 to 87.6) in patients that received enzalutamide. In four placebo-controlled trials (AFFIRM, PROSPER, PREVAIL, and ARCHES), the median duration of treatment was 14.3 months (range: <0.1 to 87.6) in the enzalutamide group [see Clinical Studies ( 14 )] . In these four trials, the most common adverse reactions (≥ 10%) that occurred more frequently (≥ 2% over placebo) in the enzalutamide-treated patients were musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhea, hypertension, hemorrhage, fall, fracture and headache. AFFIRM: Enzalutamide versus Placebo in Metastatic CRPC Following Chemotherapy AFFIRM enrolled 1,199 patients with metastatic CRPC who had previously received docetaxel. The median duration of treatment was 8.3 months with enzalutamide and 3 months with placebo. During the trial, 48% of patients on the enzalutamide arm and 46% of patients on the placebo arm received glucocorticoids. Grade 3 and higher adverse reactions were reported among 47% of enzalutamide-treated patients. Discontinuations due to adverse reactions were reported for 16% of enzalutamide-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the enzalutamide-treated patients compared to none (0%) of the placebo-treated patients. Table 1 shows adverse reactions reported in AFFIRM that occurred at a ≥ 2% higher frequency in the enzalutamide arm compared to the placebo arm. Table 1 Adverse Reactions in AFFIRM 1 CTCAE v4 2 Includes asthenia and fatigue. 3 Includes dizziness and vertigo. 4 Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. 5 Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. 6 Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection. Enzalutamide (N = 800) Placebo (N = 399) Grade 1 to 4 1 (%) Grade 3 to 4 (%) Grade 1 to 4 (%) Grade 3 to 4 (%) General Disorders Asthenic Conditions 2 51 9 44 9 Peripheral Edema 15 1 13 0.8 Musculoskeletal and Connective Tissue Disorders Back Pain 26 5 24 4 Arthralgia 21 2.5 17 1.8 Musculoskeletal Pain 15 1.3 12 0.3 Muscular Weakness 10 1.5 7 1.8 Musculoskeletal Stiffness 2.6 0.3 0.3 0 Gastrointestinal Disorders Diarrhea 22 1.1 18 0.3 Vascular Disorders Hot Flush 20 0 10 0 Hypertension 6 2.1 2.8 1.3 Nervous System Disorders Headache 12 0.9 5 0 Dizziness 3 9 0.5 7 0.5 Spinal Cord Compression and Cauda Equina Syndrome 7 7 4.5 3.8 Paresthesia 7 0 4.5 0 Mental Impairment Disorders 4 4.3 0.3 1.8 0 Hypoesthesia 4 0.3 1.8 0 Infections and Infestations Upper Respiratory Tract Infection 5 11 0 6 0.3 Lower Respiratory Tract And Lung Infection 6 8 2.4 4.8 1.3 Psychiatric Disorders Insomnia 9 0 6 0.5 Anxiety 6 0.3 4 0 Renal and Urinary Disorders Hematuria 7 1.8 4.5 1 Pollakiuria 4.8 0 2.5 0 Injury, Poisoning and Procedural Complications Fall 4.6 0.3 1.3 0 Non-pathologic Fractures 4 1.4 0.8 0.3 Skin and Subcutaneous Tissue Disorders Pruritus 3.8 0 1.3 0 Dry Skin 3.5 0 1.3 0 Respiratory Disorders Epistaxis 3.3 0.1 1.3 0.3 PREVAIL: Enzalutamide versus Placebo in Chemotherapy-naïve Metastatic CRPC PREVAIL enrolled 1,717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 1,715 received at least one dose of study drug. The median duration of treatment was 17.5 months with enzalutamide and 4.6 months with placebo. Grade 3 to 4 adverse reactions were reported in 44% of enzalutamide-treated patients and 37% of placebo-treated patients. Discontinuations due to adverse reactions were reported for 6% of enzalutamide-treated patients. The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm. Table 2 includes adverse reactions reported in PREVAIL that occurred at a ≥ 2% higher frequency in the enzalutamide arm compared to the placebo arm. Table 2 Adverse Reactions in PREVAIL 1 CTCAE v4 2 Includes asthenia and fatigue. 3 Includes dizziness and vertigo. 4 Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. 5 Includes dyspnea, exertional dyspnea, and dyspnea at rest. 6 Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. 7 Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection. Enzalutamide (N = 871) Placebo (N = 844) Grade 1 to 4 1 (%) Grade 3 to 4 (%) Grade 1 to 4 (%) Grade 3 to 4 (%) General Disorders Asthenic Conditions 2 47 3.4 33 2.8 Peripheral Edema 12 0.2 8 0.4 Musculoskeletal and Connective Tissue Disorders Back Pain 29 2 22 3 Arthralgia 21 1.6 16 1.1 Gastrointestinal Disorders Constipation 23 0.7 17 0.4 Diarrhea 17 0.3 14 0.4 Vascular Disorders Hot Flush 18 0.1 8 0 Hypertension 14 7 4.1 2.3 Nervous System Disorders Dizziness 3 11 0.3 7 0 Headache 11 0.2 7 0.4 Dysgeusia 8 0.1 3.7 0 Mental Impairment Disorders 4 6 0 1.3 0.1 Restless Legs Syndrome 2.1 0.1 0.4 0 Respiratory Disorders Dyspnea 5 11 0.6 8 0.6 Infections and Infestations Upper Respiratory Tract Infection 6 16 0 11 0 Lower Respiratory Tract And Lung Infection 7 8 1.5 4.7 1.1 Psychiatric Disorders Insomnia 8 0.1 6 0 Renal and Urinary Disorders Hematuria 9 1.3 6 1.3 Injury, Poisoning and Procedural Complications Fall 13 1.6 5 0.7 Non-Pathological Fracture 9 2.1 3 1.1 Metabolism and Nutrition Disorders Decreased Appetite 19 0.3 16 0.7 Investigations Weight Decreased 12 0.8 8 0.2 Reproductive System and Breast Disorders Gynecomastia 3.4 0 1.4 0 TERRAIN: Enzalutamide versus Bicalutamide in Chemotherapy-naïve Metastatic CRPC TERRAIN enrolled 375 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 372 received at least one dose of study drug. The median duration of treatment was 11.6 months with enzalutamide and 5.8 months with bicalutamide. Discontinuations with an adverse reaction as the primary reason were reported for 8% of enzalutamide-treated patients and 6% of bicalutamide-treated patients. The most common adverse reactions leading to treatment discontinuation were back pain and pathological fracture, which occurred in 3.8% of enzalutamide-treated patients for each event and in 2.1% and 1.6% of bicalutamide-treated patients, respectively. Table 3 shows overall and common adverse reactions (≥ 10%) in enzalutamide-treated patients. Table 3 Adverse Reactions in TERRAIN 1 CTCAE v 4 2 Including asthenia and fatigue. 3 Including musculoskeletal pain and pain in extremity. 4 Including nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. Enzalutamide (N = 183) Bicalutamide (N = 189) Grade 1 to 4 1 (%) Grade 3 to 4 (%) Grade 1 to 4 (%) Grade 3 to 4 (%) Overall 94 39 94 38 General Disorders Asthenic Conditions 2 32 1.6 23 1.1 Musculoskeletal and Connective Tissue Disorders Back Pain 19 2.7 18 1.6 Musculoskeletal Pain 3 16 1.1 14 0.5 Vascular Disorders Hot Flush 15 0 11 0 Hypertension 14 7 7 4.2 Gastrointestinal Disorders Nausea 14 0 18 0 Constipation 13 1.1 13 0.5 Diarrhea 12 0 9 1.1 Infections and Infestations Upper Respiratory Tract Infection 4 12 0 6 0.5 Investigational Weight Loss 11 0.5 8 0.5 PROSPER: Enzalutamide versus Placebo in Non-metastatic CRPC Patients PROSPER enrolled 1,401 patients with non-metastatic CRPC, of whom 1,395 received at least one dose of study drug. Patients were randomized 2:1 and received either enzalutamide at a dose of 160 mg once daily (N = 930) or placebo (N = 465). The median duration of treatment at the time of analysis was 18.4 months (range: 0 to 42 months) with enzalutamide and 11.1 months (range: 0 to 43 months) with placebo. Overall, 32 patients (3.4%) receiving enzalutamide died from adverse reactions. The reasons for death with ≥ 2 patients included coronary artery disorders (n = 7), sudden death (n = 2), cardiac arrhythmias (n = 2), general physical health deterioration (n = 2), stroke (n = 2), and secondary malignancy (n = 5; one each of acute myeloid leukemia, brain neoplasm, mesothelioma, small cell lung cancer, and malignant neoplasm of unknown primary site). Three patients (0.6%) receiving placebo died from adverse reactions of cardiac arrest (n = 1), left ventricular failure (n = 1), and pancreatic carcinoma (n = 1). Grade 3 or higher adverse reactions were reported among 31% of enzalutamide-treated patients and 23% of placebo-treated patients. Discontinuations with an adverse reaction as the primary reason were reported for 9.4% of enzalutamide-treated patients and 6% of placebo-treated patients. Of these, the most common adverse reaction leading to treatment discontinuation was fatigue, which occurred in 1.6% of the enzalutamide-treated patients compared to none of the placebo-treated patients. Table 4 shows adverse reactions reported in PROSPER that occurred at a ≥ 2% higher frequency in the enzalutamide arm than in the placebo arm. Table 4 Adverse Reactions in PROSPER 1 CTCAE v 4 2 Includes dizziness and vertigo. 3 Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. 4 Includes asthenia and fatigue. 5 Includes all osseous fractures from all sites. Enzalutamide (N = 930) Placebo (N = 465) Grade 1 to 4 1 (%) Grade 3 to 4 (%) Grade 1 to 4 (%) Grade 3 to 4 (%) Metabolism and Nutrition Disorders Decreased Appetite 10 0.2 3.9 0.2 Nervous System Disorders Dizziness 2 12 0.5 5 0 Headache 9 0.2 4.5 0 Cognitive and Attention Disorders 3 4.6 0.1 1.5 0 Vascular Disorders Hot Flush 13 0.1 8 0 Hypertension 12 4.6 5 2.2 Gastrointestinal Disorders Nausea 11 0.3 9 0 Constipation 9 0.2 7 0.4 General Disorders and Administration Site Conditions Asthenic Conditions 4 40 4 20 0.9 Investigations Weight Decreased 6 0.2 1.5 0 Injury, Poisoning and Procedural Complications Fall 11 1.3 4.1 0.6 Fractures 5 10 2 4.9 1.7 Psychiatric Disorders Anxiety 2.8 0.2 0.4 0 ARCHES: Enzalutamide versus Placebo in Metastatic CSPC Patients ARCHES randomized 1,150 patients with mCSPC, of whom 1,146 received at least one dose of study drug. All patients received either a gonadotropin-releasing hormone (GnRH) analog concurrently or had bilateral orchiectomy. Patients received either enzalutamide at a dose of 160 mg once daily (N=572) or placebo (N=574). The median duration of treatment was 12.8 months (range: 0.2 to 26.6 months) with enzalutamide and 11.6 months (range: 0.2 to 24.6 months) with placebo. Overall, 10 patients (1.7%) receiving enzalutamide died from adverse reactions. The reasons for death in ≥ 2 patients included heart disease (n=3), sepsis (n=2) and pulmonary embolism (n=2). Eight patients (1.4%) receiving placebo died from adverse reactions. The reasons for death in ≥ 2 patients included heart disease (n=2) and sudden death (n=2). Grade 3 or higher adverse reactions were reported in 24% of patients treated with enzalutamide. Permanent discontinuation due to adverse reactions as the primary reason was reported in 4.9% of enzalutamide-treated patients and 3.7% of placebo-treated patients. The most common adverse reactions resulting in permanent discontinuation in enzalutamide-treated patients were alanine aminotransferase increased, aspartate aminotransferase elevation, and seizure, each in 0.3%. The most common adverse reactions leading to permanent discontinuation in placebo-treated patients were arthralgia, and fatigue, each in 0.3%. Dose reductions due to an adverse reaction occurred in 4.4% of patients who received enzalutamide. Fatigue/asthenia was the most frequent adverse reaction requiring dose reduction in 2.1% of enzalutamide-treated patients and 0.7% of placebo-treated patients. Table 5 shows adverse reactions reported in ARCHES that occurred at a ≥ 2% higher frequency in the enzalutamide arm than in the placebo arm. Table 5 Adverse Reactions in ARCHES 1 CTCAE v 4.03. 2 Includes memory impairment, amnesia, cognitive disorder, dementia, disturbance in attention, transient global amnesia, dementia alzheimer's type, mental impairment, senile dementia and vascular dementia. 3 Includes asthenia and fatigue. 4 Includes Fracture related preferred terms under high level terms: fractures NEC; fractures and dislocations NEC; limb fractures and dislocations; pelvic fractures and dislocations; skull and brain therapeutic procedures; skull fractures, facial bone fractures and dislocations; spinal fractures and dislocations; thoracic cage fractures and dislocations. Enzalutamide (N = 572) Placebo (N = 574) Grade 1 to 4 1 (%) Grade 3 to 4 (%) Grade 1 to 4 (%) Grade 3 to 4 (%) Metabolism and Nutrition Disorders Decreased Appetite 4.9 0.2 2.6 0 Nervous System Disorders Cognitive and Memory Impairment 2 4.5 0.7 2.1 0 Restless Legs Syndrome 2.4 0 0.3 0 Vascular Disorders Hot Flush 27 0.3 22 0 Hypertension 8 3.3 6 1.7 General Disorders and Administration Site Conditions Asthenic conditions 3 24 1.7 20 1.6 Musculoskeletal and Connective Tissue Disorders Musculoskeletal Pain 6 0.2 4 0.2 Injury, Poisoning and Procedural Complications Fractures 4 6 1 4.2 1 Laboratory Abnormalities Table 8 shows laboratory abnormalities that occurred in ≥ 5% of patients, and more frequently (> 2%) in the enzalutamide arm compared to placebo in the pooled, randomized, placebo-controlled studies. Table 8 Laboratory Abnormalities Enzalutamide (N = 3,173) Placebo (N = 2,282) Grade 1 to 4 (%) Grade 3 to 4 (%) Grade 1 to 4 (%) Grade 3 to 4 (%) Hematology Hemoglobin decreased 50 1.8 47 1.5 Neutrophil count decreased 20 0.9 17 0.4 White blood cell decreased 17 0.4 9.8 0.2 Chemistry Hyperglycemia 83 3.2 75 3.1 Hypermagnesemia 16 0.1 13 0 Hyponatremia 13 1.4 8.6 1.5 Hypophosphatemia 10 1.4 7 0.8 Hypercalcemia 6.8 0.1 4.5 0 Hypertension In the combined data from four randomized placebo-controlled clinical trials, hypertension was reported in 12% of patients receiving enzalutamide and 5% of patients receiving placebo. Medical history of hypertension was balanced between arms. Hypertension led to study discontinuation in < 1% of patients in each arm. 6.2 Post-Marketing Experience The following additional adverse reactions have been identified during post approval use of enzalutamide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal Disorders: vomiting, dysphagia (including choking related to enzalutamide product size Immune System Disorders: hypersensitivity (edema of the face, tongue, lip, or pharynx) Neurological Disorders: posterior reversible encephalopathy syndrome (PRES), dysgeusia Skin and Subcutaneous Tissue Disorders: rash, severe cutaneous adverse reactions (including Stevens-Johnson syndrome (SJS), erythema multiforme, toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP))
adverse reactions table
<table ID="ID376" width="626" styleCode="Noautorules"><caption> Table 1 Adverse Reactions in AFFIRM </caption><col width="217"/><col width="108"/><col width="101"/><col width="100"/><col width="100"/><tfoot><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>1 </sup> CTCAE v4</paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>2 </sup> Includes asthenia and fatigue.</paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>3 </sup> Includes dizziness and vertigo.</paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>4 </sup> Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.</paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>5</sup> Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. </paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>6</sup> Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.</paragraph></td></tr></tfoot><tbody><tr><td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule"/><td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center"><content styleCode="bold"> Enzalutamide</content> <content styleCode="bold"> (N = 800)</content> </td><td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center"><content styleCode="bold"> Placebo</content> <content styleCode="bold"> (N = 399)</content> </td></tr><tr><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 1 to 4<content styleCode="italics"><sup>1</sup></content></content> <content styleCode="bold"> (%)</content> </td><td valign="top" styleCode=" Toprule Botrule Rrule" align="center"><content styleCode="bold"> Grade 3 to 4 (%)</content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 1 to 4 (%)</content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 3 to 4 (%)</content> </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> General Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Asthenic Conditions<content styleCode="italics"><sup>2</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 51 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 9 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 44 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 9 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Peripheral Edema </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 15 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 13 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.8 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Musculoskeletal and Connective Tissue Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Back Pain </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 26 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 24 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Arthralgia </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 21 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 17 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.8 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Musculoskeletal Pain </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 15 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 12 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Muscular Weakness </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 10 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.8 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Musculoskeletal Stiffness </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Gastrointestinal Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Diarrhea </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 22 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 18 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Vascular Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hot Flush </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 20 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 10 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypertension </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Nervous System Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Headache </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 12 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.9 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dizziness<content styleCode="italics"><sup>3</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 9 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.5 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Spinal Cord Compression and Cauda Equina Syndrome </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3.8 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Paresthesia </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Mental Impairment Disorders<content styleCode="italics"><sup>4</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypoesthesia </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Infections and Infestations</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Upper Respiratory Tract Infection<content styleCode="italics"><sup>5</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 11 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Lower Respiratory Tract And Lung Infection<content styleCode="italics"><sup>6</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Psychiatric Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Insomnia </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 9 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.5 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Anxiety </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Renal and Urinary Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hematuria </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Pollakiuria </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Injury, Poisoning and Procedural Complications</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Fall </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Non-pathologic Fractures </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Skin and Subcutaneous Tissue Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Pruritus </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dry Skin </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Respiratory Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Epistaxis </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td></tr></tbody></table>
adverse reactions table
<table ID="ID378" width="593" styleCode="Noautorules"><caption> Table 2 Adverse Reactions in PREVAIL </caption><col width="199"/><col width="102"/><col width="96"/><col width="102"/><col width="94"/><tfoot><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>1</sup> CTCAE v4</paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>2</sup> Includes asthenia and fatigue.</paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>3</sup> Includes dizziness and vertigo.</paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>4</sup> Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. </paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>5</sup> Includes dyspnea, exertional dyspnea, and dyspnea at rest.</paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>6 </sup>Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. </paragraph></td></tr><tr><td align="left" colspan="5"><paragraph styleCode="Footnote"><sup>7</sup> Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.</paragraph></td></tr></tfoot><tbody><tr><td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule"/><td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center"><content styleCode="bold"> Enzalutamide</content> <content styleCode="bold"> (N = 871)</content> </td><td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center"><content styleCode="bold"> Placebo</content> <content styleCode="bold"> (N = 844)</content> </td></tr><tr><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 1 to 4<content styleCode="italics"><sup>1</sup></content></content> <content styleCode="bold"> (%)</content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 3 to 4 (%)</content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 1 to 4 (%)</content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 3 to 4 (%)</content> </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> General Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Asthenic Conditions<content styleCode="italics"><sup>2</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 47 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3.4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 33 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.8 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Peripheral Edema </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 12 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.4 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Musculoskeletal and Connective Tissue Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Back Pain </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 29 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 22 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Arthralgia </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 21 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 16 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Gastrointestinal Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Constipation </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 23 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 17 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.4 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Diarrhea </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 17 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 14 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.4 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Vascular Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hot Flush </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 18 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypertension </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 14 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.3 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Nervous System Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dizziness<content styleCode="italics"><sup>3</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 11 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Headache </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 11 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.4 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dysgeusia </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3.7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Mental Impairment Disorders<content styleCode="italics"><sup>4</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Restless Legs Syndrome </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Respiratory Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dyspnea<content styleCode="italics"><sup>5</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 11 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.6 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Infections and Infestations</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Upper Respiratory Tract Infection<content styleCode="italics"><sup>6</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 16 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 11 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Lower Respiratory Tract And Lung Infection<content styleCode="italics"><sup>7</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Psychiatric Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Insomnia </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Renal and Urinary Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hematuria </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 9 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.3 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Injury, Poisoning and Procedural Complications</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Fall </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 13 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.7 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Non-Pathological Fracture </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 9 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 2.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Metabolism and Nutrition Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Decreased Appetite </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 19 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.3 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 16 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.7 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Investigations</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Weight Decreased </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 12 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 </td></tr><tr><td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Reproductive System and Breast Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Gynecomastia </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 3.4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.4 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr></tbody></table>
adverse reactions table
<table ID="ID380" width="599" styleCode="Noautorules"><caption> Table 3 Adverse Reactions in TERRAIN </caption><col width="198"/><col width="102"/><col width="96"/><col width="1"/><col width="101"/><col width="102"/><tfoot><tr><td align="left" colspan="6"><paragraph styleCode="Footnote"><sup>1</sup> CTCAE v 4 </paragraph></td></tr><tr><td align="left" colspan="6"><paragraph styleCode="Footnote"><sup>2</sup> Including asthenia and fatigue. </paragraph></td></tr><tr><td align="left" colspan="6"><paragraph styleCode="Footnote"><sup>3</sup> Including musculoskeletal pain and pain in extremity. </paragraph></td></tr><tr><td align="left" colspan="6"><paragraph styleCode="Footnote"><sup>4</sup> Including nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.</paragraph></td></tr></tfoot><tbody><tr><td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule"/><td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center"><content styleCode="bold"> Enzalutamide</content> <content styleCode="bold"> (N = 183)</content> </td><td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center"><content styleCode="bold"> Bicalutamide</content> <content styleCode="bold"> (N = 189)</content> </td></tr><tr><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 1 to 4<content styleCode="italics"><sup>1</sup></content></content> <content styleCode="bold"> (%)</content> </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 3 to 4 (%)</content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 1 to 4 (%)</content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"><content styleCode="bold"> Grade 3 to 4 (%)</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Overall </content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 94 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 39 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 94 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 38 </td></tr><tr><td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> General Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Asthenic Conditions<content styleCode="italics"><sup>2</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 32 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 1.6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 23 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 </td></tr><tr><td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Musculoskeletal and Connective Tissue Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Back Pain </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 19 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 2.7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 18 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.6 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Musculoskeletal Pain<content styleCode="italics"><sup>3</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 16 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 14 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.5 </td></tr><tr><td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Vascular Disorders</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hot Flush </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 15 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 11 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypertension </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 14 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 7 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 4.2 </td></tr><tr><td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Gastrointestinal Disorders</content> </td></tr><tr><td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Nausea </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 14 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 18 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Constipation </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 13 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 13 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.5 </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Diarrhea </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 12 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 9 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 1.1 </td></tr><tr><td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Infections and Infestations</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Upper Respiratory Tract Infection<content styleCode="italics"><sup>4</sup></content> </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 12 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 0 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 6 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.5 </td></tr><tr><td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left"><content styleCode="bold"> Investigational</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Weight Loss </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 11 </td><td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 0.5 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 8 </td><td valign="top" styleCode=" Botrule Rrule" align="center"> 0.5 </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.